NINatalie M. Isenberg

Natalie M. Isenberg

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Natalie M. Isenberg has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Ripening of Rh Nanoparticle Catalysts in Reverse Water–Gas Shift via a Data-Driven Model Combining Physics, Theory, and Experiment

    by Natalie M. Isenberg, Yonghyuk Lee, Carolina Colombo Tedesco, Zhihengyu Chen, Anastassia N. Alexandrova, Christopher J. Tassone, Robert Rallo, Simon R. Bare

  • Open Access

    LABMATE: Language Model Based Multi-Agent System to Accelerate Catalysis Experiments

    by Anurag Acharya, Anshu Kiran Sharma, Derek Parker, Timothy Vega, Rizwan A. Ashraf, Natalie M. Isenberg, Jan Strube, Robert Rallo


  • Top Cited Papers
    Open Access

    Bayesian optimization algorithms for accelerator physics

    by Ryan Roussel, Auralee L. Edelen, Tobias Boltz, Dylan Kennedy, Zhe Zhang, Fuhao Ji, Xiaobiao Huang, Daniel Ratner, Andrea Santamaria Garcia, Chenran Xu, et al.

    Accelerator physics relies on numerical algorithms to solve optimization problems in online accelerator control and tasks such as experimental design and model calibration in simulations. The effectiveness of optimization algorithms in discovering ideal solutions for complex challenges with limited resources often determines the problem complexity these methods can address. The accelerator physics community has recognized the advantages of Bayesian optimization algorithms, which leverage statistical surrogate models of objective functions to effectively address complex optimization challenges, especially in the presence of noise during accelerator operation and in resource-intensive physics simulations. In this review article, we offer a conceptual overview of applying Bayesian optimization techniques toward solving optimization problems in accelerator physics. We begin by providing a straightforward explanation of the essential components that make up Bayesian optimization techniques. We then give an overview of current and previous work applying and modifying these techniques to solve accelerator physics challenges. Finally, we explore practical implementation strategies for Bayesian optimization algorithms to maximize their performance, enabling users to effectively address complex optimization challenges in real-time beam control and accelerator design. Published by the American Physical Society 2024


  • Open Access

    Pharmacodynamic model of PARP1 inhibition and global sensitivity analyses can lead to cancer biomarker discovery

    by Susan D. Mertins, Natalie M. Isenberg, Kristopher-Roy Reyes, Byung-Jun Yoon, Nathan Urban, Manasi P. Jogalekar, Morgan E. Diolaiti, Michael Ryan Weil, Eric A. Stahlberg

    Pharmacodynamic models provide inroads to understanding key mechanisms of action and may significantly improve patient outcomes in cancer with improved ability to determine therapeutic benefit. Additionally, these models may also lead to insights into potential biomarkers that can be utilized for prediction in prognosis and therapeutic decisions. As an example of this potential, here we present an advanced computational Ordinary Differential Equation (ODE) model of PARP1 signalling and downstream effects due to its inhibition. The model has been validated experimentally and further evaluated through a global sensitivity analysis. The sensitivity analysis uncovered two model parameters related to protein synthesis and degradation rates that were also found to contribute the most variability to the therapeutic prediction. Because this variability may define cancer patient subpopulations, we interrogated genomic, transcriptomic, and clinical databases, to uncover a biomarker that may correspond to patient outcomes in the model. In particular, GSPT2, a GTPase with translation function, was discovered and if mutations serve to alter catalytic activity, its presence may explain the variability in the model’s parameters. This work offers an analysis of ODE models, inclusive of model development, sensitivity analysis, and ensuing experimental data analysis, and demonstrates the utility of this methodology in uncovering biomarkers in cancer. Author summary: Because biochemical reaction networks are complex, dynamic, and typically provide output that results from non-linear interactions, mathematical models of such offer insight into cell function. In the clinic, models including drug action further their usefulness in that they may predict therapeutic outcome and other useful markers such as those for prognosis. In this study, we report a model of drug action that targets a critical protein, that when inhibited, promotes tumor cell death and documented remissions. Because all patients do not respond to the described treatment, a means to find cancer patient subpopulations that might benefit continues to be a challenge. Therefore, we analyzed the pharmacodynamic model by defining the parameters of the greatest variability and interrogated genomic, transcriptomic, and clinical cohort databases with this information and discovered a novel biomarker associated with prognosis in some ovarian and uterine cancer patients and separately, associated with the potential to respond to treatment.